Arcellx, Inc.
ACLX
Classifica tra le azioni
#2779
Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to... Arcellx, Inc. is a clinical-stage biotechnology enterprise dedicated to pioneering immunotherapeutic solutions for patients battling cancer and other intractable diseases. A cornerstone of their pipeline is CART-ddBCMA, an advanced ddCAR product candidate currently undergoing a Phase 1 clinical trial. This investigational treatment targets individuals suffering from relapsed or refractory multiple myeloma (MM). Beyond their lead candidate, Arcellx is also advancing ACLX-001, an immunotherapy composed of ARC-T cells and bi-valent SparX proteins engineered to combat r/r MM by targeting BCMA. Their development efforts extend to ACLX-002 and ACLX-003, designed to address relapsed or refractory acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS), alongside a broader portfolio of additional AML/MDS candidates and programs focused on solid tumors. The company, headquartered in Gaithersburg, Maryland, was established in 2014. It operated as Encarta Therapeutics, Inc. before adopting its current name, Arcellx, Inc., in January 2016.
Prezzo delle azioni
$115.07
Ultima sincronizzazione: 2026-05-15
Capitalizzazione di mercato
$6.73B
Variazione (1 giorno)
0.00%
Variazione (1 anno)
32.61%
Paese
US
Scambia Arcellx, Inc. (ACLX)
Categoria
Healthcare
Utile per Arcellx, Inc. (ACLX)
Utile nel Dec 2025 TTM: $-228.87M
Secondo gli ultimi rapporti finanziari di Arcellx, Inc., gli utili attuali della società sono $-228.87M. Nel 2023, la società ha registrato un utile di $-70.03M, un aumento rispetto a agli utili del 2022, che erano di $-188.68M. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Storico degli utili di Arcellx, Inc. dal 2018 al 2026
Utile alla fine di ogni anno
| Anno | Utile | Cambia |
|---|---|---|
| 2026 (TTM) | $-228.87M | 117.39% |
| 2024 | $-105.28M | 50.34% |
| 2023 | $-70.03M | -62.89% |
| 2022 | $-188.68M | 190.41% |
| 2021 | $-64.97M | 102.43% |
| 2020 | $-32.10M | 78.58% |
| 2019 | $-17.97M | 116.32% |
| 2018 | $-8.31M | 0.00% |
Utile per aziende simili o concorrenti
| Azienda | Utile | Differenza negli utili | Il paese |
|---|---|---|---|
| $5.27B | -2,404.81% |
US
|
|
| $-3.09B | 1,248.83% |
US
|
|
| $-4.02B | 1,654.83% |
AU
|
|
| - | - |
CH
|
|
| $1.95B | -952.31% |
NL
|
